Home > Insider Trading > Filing (0000899243-20-030340)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1593899	Atea Pharmaceuticals Inc.	AVIR	Pharmaceutical Preparations (2834)	460574869

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657434	F. A. Andrew Hack	C/O Bain Capital Life Sciences Investors, 200 Clarendon Street Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-11-03	5,365,659	$0.00	5,365,659	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2020-11-03	250,000	$24.00	5,615,659	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Convertible Preferred Stock	Disposition	2020-11-03	3,383,190	$0.00	3,383,190	$0.00
Common Stock	Series D-1 Convertible Preferred Stock	Disposition	2020-11-03	1,982,469	$0.00	1,982,469	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities").
Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.
On November 3, 2020, BCLS II Investco purchased 250,000 shares of common stock of the Issuer at a price of $24.00 per share, pursuant to an underwritten public offering.